<DOC>
	<DOCNO>NCT00172120</DOCNO>
	<brief_summary>TRES evaluate effect continue ALX1-11 treatment safety efficacy variable assess OLE study maximum treatment duration 36 month OLES TRES combine .</brief_summary>
	<brief_title>Open Label Extension</brief_title>
	<detailed_description>The primary goal osteoporosis therapy prevent fracture , anabolic agent accomplish strengthen bone structure , accompany change BMD . Effects ALX1-11 BMD previously document dose-finding Phase II clinical trial osteoporotic postmenopausal woman take calcium vitamin D supplement , otherwise naive osteoporosis therapy . The anabolic effect ALX1-11 lumbar vertebra statistically significant compare placebo 12 month treatment . In addition , animal study show new bone form treatment ALX1 11 good quality histologically biomechanically ( Mosekilde et al. , 1991 ; Kimmel et al. , 1993 ) . Protocol ALX1-11-93001 ( TOP ) assess effect 18 month ALX1-11 treatment fracture incidence primary efficacy variable , Protocol CL1-11-002 ( OLES ) assess effect BMD 24 month treatment . Subjects enrol current study ( TRES ) receive placebo TOP ALX1-11 OLES . TRES evaluate effect continue ALX1-11 treatment safety efficacy variable assess OLE study maximum treatment duration 36 month OLES TRES combine .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Received placebo TOP Completed 18 month daily treatment ALX111 OLES Received last dose ALX111 OLES within 3 month ( 90 day ) dose study Have ability continue selfadminister , designee administer , daily injection Have ability understand , willingness sign , informed consent form ( ICF ) Subjects exclude developed exclusion criterion OLES , modification list . Concurrent Diseases Subjects exclude developed disease illness list since enrollment OLES . Immune.Significant* immunological disorder ; include AIDSAllergies ALX111 constituent Endocrine.Significant* endocrine disorder , include hyper hypoparathyroidism , Cushing 's disease , hyperthyroidism Gastrointestinal ( GI ) .Significant* GI disorder Kidney Collecting.Significant* renal disorder impair renal function , nephrolithiasis urolithiasis , verify kidney calcification , etc . Liver , biliary tract , pancreatic.Significant* hepatic pancreatic disorder , active hepatitis , pancreatitis Musculoskeletal.Metabolic bone disease , eg. , Paget 's disease , osteogenesis imperfecta , osteomalacia Chronic , active joint disease and/or joint infection Neoplasia.Cancer , exception squamous basal cell carcinoma** Nervous.Significant* neurological psychiatric disease Vascular , respiratory , cardiac.Significant* unstable cardiac pulmonary disease ( * ) Significance determine investigator basis history , physical exam , and/or laboratory screen . Significant disorder necessitate ongoing change therapeutic medication frequent monitoring . ( ** ) Subjects either squamous basal cell carcinoma skin enroll : 1 . The lesion ( ) fully resect clear margin describe write report pathologist , AND 2 . The subject recurrence lesion least 1 year time original resection Prohibited Concomitant Medications PTH analogs* Fluoride Strontium Calcitonin Vitamin D metabolites analog ( eg. , calcitriol ) Immunomodulatory agent antiproliferative activity Cytostatics** Thyroxine . Prohibited dose &gt; 0.2 mg/day ( see Table 44 allow condition ) Bisphosphonate Anabolic steroid androgen ( * ) PTH ( parathyroid hormone ) analog include PTH ( 134 ) , PTHrP , analog ( ** ) eg , azathioprine , recombinant human tumor necrosis fusion ( Fc ) protein , monoclonal antibody tumor necrosis factor ( e.g. , infliximab [ Remicade™ ] ) Medications Requiring Washout Period Subjects complete OLES begin take medication list follow table may enroll study washout period 30 day . Hormonereplacement therapy* Methotrexate SERMs** Any investigational drug Other medication know affect metabolism bone 30 day PMO approval ( * ) Includes estrogen estrogen/progesteronereplacement therapy give oral , transdermal , intramuscular administration b SERMs ( selective estrogen receptor modulator ) include tamoxifen raloxifene ( Evista® ) PMO = project medical officer ( ** ) SERMs ( selective estrogen receptor modulator ) include tamoxifen raloxifene ( Evista® ) PMO = project medical officer Medications Allowed Specific Conditions Are MetMedications allow specific condition list : Thyroid hormone . At stable dose &lt; = 0.2 mg/day Thiazide . At stable dose Vaginal application estrogencontaining cream . Conjugated estrogen estradiol dose &lt; =0.5 g administer twice week ( total 1.0 g weekly ) . Estrace® ( Ogen ) dose &lt; =1.0 g twice week ( total 2.0 g weekly ) Systemic corticosteroid . Acute bolus steroid ( oral injectable ) selflimited illness allow following condition : 1 . Exposure steroid limit £30 consecutive day 2 . Maximal dose ( prednisoneequivalent ) exceed 225 mg ( 5 mg/day 30 day ) 3 . Illness acute nature expect recur remain treatment period study Inhaled corticosteroid . At dose &lt; 1200 mg/day beclomethasone equivalent Intraarticular injection . A single intraarticular injection allow every 6 month dose corticosteroid inject less equivalent dose prednisone 40 mg suspension Phenytoin . No phenytoin exposure allow within 5 year Month 0 TOP . Allowed last phenytoin exposure &gt; 15 year prior screen TOP 515 year screen TOP &lt; 2 month duration Provera® ( medroxyprogesterone ) . Allowed used accord label Laboratory Values Physical Examination Findings For excluded laboratory value , level show follow table upper limit exclusion base specific test result , exception calculate creatinine clearance serum 25 ( OH ) vitamin D , limit low . All exclusionary laboratory result confirm repeat test . Subjects may exclude clinically abnormal value , determine investigator . Fasting serum total calcium ( Ca ) . Subject exclude value* &gt; 10.2 mg/dL** , *** 24hour urinary Ca . Subject exclude value* &gt; 360 mg/day** Serum total alkaline phosphatase . Subject exclude value* 3X upper limit normal laboratory Serum PTH*** . Subject exclude value* &gt; 50 pg/mL Calculated creatinine clearance*** Subject exclude value* &lt; 50 mL/minute Serum 25 ( OH ) vitamin D*** . Subject exclude value* &lt; 20 ng/mL ( * ) Exclude subject repeat assessment confirm result . ( ** ) Not use reason premature discontinuation study . Subjects elevate value enrollment manage appropriate algorithm ( Appendices 2 3 ) . ( *** ) Not exclusion criterion OLES Substance AbuseSubjects exclude history alcohol and/or drug abuse determine investigator . ComplianceSubjects may exclude suspect confirmed poor compliance complete clinical trial evaluation and/or questionnaire .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Post-menopausal</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Parathyroid Hormone</keyword>
	<keyword>PTH</keyword>
	<keyword>ALX1-11</keyword>
</DOC>